NCT05556291

Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study

Efficacy, Safety & Tolerability of Combination of Ertugliflozin and Sitagliptin in Patients With Type II Diabetes Mellitus

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 190 (actual)
• Sponsor: Getz Pharma · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study to evaluate the efficacy, safety and tolerability of Ertugliflozin and Sitagliptin Con-initiation in patients with Type II Diabetes Mellitus in the Pakistani population. The study duration will be 12 months.

Conditions

• Efficacy
• Safety
• Tolerability

Interventions

Type	Name	Description
DRUG	Combinations of Oral Blood Glucose Lowering Drugs	Combination of Ertugliflozin and Sitagliptin

Timeline

• Start date: 2022-12-01
• Primary completion: 2024-07-01
• Completion: 2024-12-01
• First posted: 2022-09-27
• Last updated: 2025-03-20

Locations

3 sites across 1 country: Pakistan

Regulatory

• FDA-regulated drug study